Results showed that naïve patients had high levels of CD137+ T cells (total, CD8, and CD4) compared to platinum-doublet chemotherapy-treated patients, demonstrating that chemotherapy negatively impacts the immune activatory profile of cancer patients. Here, TNFRSF9 is linked to cancer.